05:06 AM EDT, 08/06/2026 (MT Newswires) -- United Securities LLC downwardly revised its price target on Nahdi Medical (SASE:4164) after the pharmaceutical retailer's second-quarter results. "[We] believe subdued consumer demand, intense competitive dynamics, and ongoing geopolitical uncertainty will continue to weigh on near-term performance. Following the 2Q26 results, we maintain our 2026e revenue and earnings forecasts but marginally reduce our target price to SAR 104.53 per share to reflect a higher risk premium. Accordingly, we reiterate our Hold recommendation on the stock," analysts said Wednesday. The company logged a 9.7% annual decline in net profit to 215 million Saudi riyals, 4.1% below United Securities' estimate. Revenue, meanwhile, rose 5.8% year over year, which was broadly in line with the research firm's forecast.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.